Advertisement


Masood Moghul, PhD, on a Mobile Prostate Cancer Clinical Unit: Findings From the Man Van

2025 ASCO GU

Advertisement

Masood Moghul, PhD, of The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, describes the impact of a nurse-led mobile clinical unit on targeted screening invitations to men at high risk for prostate cancer in disadvantaged communities in London (Abstract 317).



Related Videos

Prostate Cancer
Supportive Care

Benjamin Maughan, MD, PharmD, on Exercise Therapy for Patients With Advanced Prostate Cancer

Benjamin Maughan, MD, PharmD, of Huntsman Cancer Institute, discusses the effects of a 12-week, structured, guided exercise program called Personal Optimism With Exercise Recovery (POWER) on fatigue and peak aerobic exercise capacity in patients with advanced prostate cancer receiving androgen-deprivation therapy (Abstract 120).

Prostate Cancer

Michael Schweizer, MD: EZH2 Inhibitor Plus Enzalutamide in mCRPC

Michael Schweizer, MD, of the University of Washington and Fred Hutchinson Cancer Center, discusses findings from a randomized dose-expansion study of the investigational EZH2 inhibitor mevrometostat in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (Abstract LBA138).

Prostate Cancer

Omid Yazdanpanah, MD, on Metastatic Castration-Resistant Prostate Cancer: LuPSMA With or Without ARPIs

Omid Yazdanpanah, MD, of the University of California, Irvine, presents findings from a secondary analysis of the VISION trial, which compared the efficacy and safety of LuPSMA in patients treated with vs without concomitant androgen receptor pathway inhibitors (ARPIs) (Abstract 121).

Prostate Cancer

Karim Fizazi, MD, PhD, on HRR-Deficient mCRPC: Final Overall Survival in TALAPRO-2

Karim Fizazi, MD, PhD, of Institut Gustave Roussy, University of Paris-Saclay, reviews final overall survival results from cohort 2 of the phase III TALAPRO-2 trial, which investigated the combination of talazoparib and enzalutamide in patients with homologous recombination repair (HRR)-deficient metastatic castration-resistant prostate cancer (mCRPC) (Abstract LBA141).

Prostate Cancer

William Aronson, MD, on a Specialized Diet in Men on Active Surveillance for Prostate Cancer

William Aronson, MD, of the VA Greater Los Angeles Healthcare System, discusses findings from the CAPFISH-3 trial, which investigated whether a high omega-3, low omega-6 fatty acid diet with fish oil capsules decreased Ki-67 levels in men with prostate cancer on active surveillance (Abstract 312).

Advertisement

Advertisement




Advertisement